0 CHECKOUT

DAIICHI SANKYO - Edoxaban Gets Edge as Key Japanese Factor-Xa Inhibitors Fall!

  • ID: 1938094
  • September 2011
  • Region: Japan
  • MP Advisors

Recent failures of Edoxaban’s key competitor factor-Xa inhibitors from Japan - YM 150 (Astellas) and TAK-442 (Takeda), the closest candidate in Japan now is Xarelto (Bayer), which is still ~1 years away from hitting the market. Edoxaban is the first and only approved factor-Xa inhibitor in Japan for prevention of VTE, though Japanese VTE opportunity is not big but it will enhance investors’ confidence regarding its global success where the opportunity is huge. Edoxaban is behind Xarelto in development for AF (~2 years). However, considering its high market potential it remains attractive as it is the only drug that has shown dose response in this class

Note: Product cover images may vary from those shown

- Edoxaban
- YM150
- TAK-442
- Factor Xa candidates
- Xarelto
- Apixaban
- ICT data
- VTE
- AF
- Factor Xa pipeline
- Anticoagulants market
- Betrixaban
- Astellas
- Takeda
- Bayer

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: This company profile will be emailed to you. The company profile is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: This company profile will be emailed to you. The company profile is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: This company profile will be emailed to you. The company profile is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS

Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer, Inc.